Posted by Michael Wonder on 24 Mar 2021
REN001 granted fast track designation by FDA for patients with primary mitochondrial myopathies
24 March 2021 - Reneo Pharmaceuticals today announced that the United States FDA granted fast track designation to REN001 for the treatment of patients with primary mitochondrial myopathies.
REN001 is an oral selective peroxisome proliferator-activated receptor delta agonist currently in clinical development for three rare genetic mitochondrial diseases.
